

“What’s New” Medical Pharmaceutical Policy August 2024 Updates

The following policy updates and reviews apply to all GHP members (Commercial, Marketplace, TPA, Medicare and Medicaid):

The following policies were reviewed with no changes:

- MBP 108.0 Kadcyła (ado-trastuzumab emtansine)
- MBP 115.0 Cyramza (ramucirumab)
- MBP 143.0 Praxbind (idarucizumab)
- MBP 149.0 Ameluz (aminolevulinic acid)
- MBP 151.0 Spinraza (nusinersen)
- MBP 162.0 Yescarta (axicabtagene ciloleucel)
- MBP 183.0 Andexxa (andexanet alfa)
- MBP 200.0 Polivy (polatuzumab vedotin-piiq)
- MBP 237.0 Zynlonta (loncastuximab tesirine-lpyl)
- MBP 238.0 Nulibry (fosdenopterin)
- MBP 257.0 Opdualag (nivolumab and relatlimab-rmbw)
- MBP 258.0 Ryplazim (plasminogen, human-tvmh)
- MBP 261.0 Anjeso (meloxicam injection)
- MBP 262.0 Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound)
- MBP 263.0 Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
- MBP 279.0 Korsuva (difelikefalin)
- MBP 280.0 Lunsumio (mosunetuzumab-axgb)
- MBP 281.0 Rebyota (fecal microbiota, live-jslm)
- MBP 282.0 Skysona (elivaldogene autotemcel)
- MBP 283.0 Tzield (teplizumab-mzwv)
- MBP 284.0 Xenpozyme (olipudase alfa-rpcp)
- MBP 285.0 Zynyz (retifanlimab-dlwr)
- MBP 287.0 Aduhelm (aducanumab-avwa)

The following policies were retired (MEDICAID ONLY):

- MBP 276.0 Zynlego (betibeglogene autotemcel) – New policy applies.

The following policy updates and reviews apply to Commercial, Marketplace, TPA, and Medicare GHP members only:

The following policies were reviewed with no changes:

- MBP 57.0 Tysabri (natalizumab)
- MBP 145.0 Cinqair (reslizumab)
- MBP 155.0 Ocrevus (ocrelizumab)
- MBP 218.0 Vyepiti (eptinezumab-jjmr)
- MBP 240.0 Fensolvi (leuprolide)
- MBP 265.0 Igalmi (dexmedetomidine)
- MBP 276.0 Zynlego (betibeglogene autotemcel)
- MBP 295.0 Briumvi (ublituximab-xiyy)